Can Dynavax's stock rebound after a dreadful 2019?
The drugmaker's planned metamorphosis failed to impress investors, but that wasn't its only headwind.
Canopy Growth and Cronos Group are in a class of their own among legal pot plays.
Biogen's decision to forgo a major deal weighed on its shares in 2019.
AbbVie's shares had an off year in 2019. Here's why.
Which of these two biotech giants is the better buy in 2020?
The Canadian cannabis grower and distributor had a dreadful 2019 that sent its shares tumbling to levels that could be tempting for bargain hunters.
Wall Street has high hopes for this mid-cap biotech in the coming year.
Aurora Cannabis and HEXO could be in serious trouble.
Acadia Pharmaceuticals and Axsome Therapeutics are top buyout candidates heading into the new year.
AbbVie and Gilead Sciences are two outstanding dividend growth plays for 2020. Here's why.
Minerva's shares are crumbling today on the heels of a major clinical setback.
Clovis' $250 million mixed shelf offering isn't sitting well with shareholders today.
Axsome's clinical pipeline has scored yet another win.
Vascepa is now in position to become a blockbuster medication.
Sarepta scored a surprise regulatory win yesterday.
The biotech titan is poised for another strong year in 2020.
Like all pot stocks, Aurora is going through a rough patch at the moment. Should long-term investors take advantage of this downturn to build a position?
Amarin and Aurinia will probably be bought out before the end of 2020. Here's why.
Which of these two Canadian pot stocks offers the better long-term opportunity for investors?